EyePoint Pharmaceuticals To Highlight DURAVYUTM Clinical And Regulatory Developments At R&D Day 2024

6/26/24 8:06:00 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $EYPT alert in real time by email

– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 –

– Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy –

– Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled –

– EyePoint to webcast its R&D Day event today at 8:00 a.m. ET –

Get the next $EYPT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EYPT

Date	Price Target	Rating	Analyst
1/7/2025	$33.00	Buy	Citigroup
10/16/2024		Sector Outperform	Scotiabank
8/28/2024	$15.00	Buy	Jefferies
1/22/2024	$35.00	Overweight	JP Morgan
11/2/2023	$20.00	Buy	Mizuho
4/21/2023	$33.00	Outperform	Robert W. Baird
7/7/2022	$21.00	Buy	Chardan Capital Markets
11/15/2021	$15.00 → $24.00	Buy	HC Wainwright & Co.

More analyst ratings

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025 – – Conference call to be held today, February 5, 2025 at 8:00 a.m. ET – WATERTOWN, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmac
2/5/25 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET. A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. About EyePoint Pharmaceuticals EyePoint (NASDAQ:EYPT) is a clinical-stage biophar
1/30/25 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee
1/16/25 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials

$EYPT
Leadership Updates

Live Leadership Updates

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San
1/8/25 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future
9/4/24 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists
4/2/24 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025 – – Conference call to be held today, February 5, 2025 at 8:00 a.m. ET – WATERTOWN, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmac
2/5/25 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials
EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments
– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in 2024 – – Positive twelve-month data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD continue to demonstrate favorable safety and efficacy – – Phase 2 VERONA trial of DURAVYU in DME fully enrolled with topline data anticipated in Q1 2025 – – $280.2 million of cash and investments on June 30, 2024, with cash runway through Phase 3 wet AMD topline data for DURAVYU in 2026 – WATERTOWN, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative thera
8/7/24 7:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy – – Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled – – EyePoint to webcast its R&D Day event today at 8:00 a.m. ET – WATERTOWN, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to
6/26/24 8:00:00 AM ET
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials

EyePoint Pharmaceuticals To Highlight DURAVYUTM Clinical And Regulatory Developments At R&D Day 2024

Chat with this insight

Recent Analyst Ratings for $EYPT

$EYPT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Dicicco Wendy F bought $19,997 worth of shares (2,567 units at $7.79), increasing direct ownership by 35% to 9,967 units (SEC Form 4)

Director Ando Goran bought $39,750 worth of shares (5,000 units at $7.95), increasing direct ownership by 61% to 13,150 units (SEC Form 4)

Director Zaderej Karen L. bought $99,750 worth of shares (12,500 units at $7.98), increasing direct ownership by 312% to 16,500 units (SEC Form 4)

$EYPT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Duker Jay S. converted options into 7,000 shares and covered exercise/tax liability with 2,055 shares, increasing direct ownership by 7% to 77,651 units (SEC Form 4)

Chief Financial Officer Elston George converted options into 5,834 shares, increasing direct ownership by 8% to 75,550 units (SEC Form 4)

Director Lurker Nancy converted options into 20,000 shares, increasing direct ownership by 11% to 205,436 units (SEC Form 4)

$EYPT Press Releases

Fastest customizable press release news feed in the world

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

$EYPT Leadership Updates

Live Leadership Updates

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

$EYPT Financials

Live finance-specific insights

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

$EYPT SEC Filings

EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$EYPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

Scotiabank initiated coverage on EyePoint Pharmaceuticals

Jefferies initiated coverage on EyePoint Pharmaceuticals with a new price target

$EYPT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

Recent Analyst Ratings for
$EYPT

$EYPT
Insider Purchases

$EYPT
Insider Trading

$EYPT
Press Releases

$EYPT
Leadership Updates

$EYPT
Financials

$EYPT
SEC Filings

$EYPT
Analyst Ratings

$EYPT
Large Ownership Changes